Physician profile
Lorrie Ball
NPI 1144982430
$2,506.32
in general payments reported to CMS, 2019-2025
21 companies · $735 in 2025
The $735 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $715 · 2023: $423 · 2024: $633 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739 · Education: $51.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.23 |
| Education | $51.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $576.95 | 2022-2025 | Farxiga, Lokelma |
| Amgen INC. | $275.75 | 2022-2025 | Parsabiv, Aranesp, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $228.32 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $171.22 | 2022-2025 | Jynarque |
| Travere Therapeutics, INC. | $147.92 | 2023-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $133.71 | 2024 | Rayaldee |
| Novo Nordisk INC | $130.23 | 2024-2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $123.35 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $118.76 | 2022 | |
| Mallinckrodt Hospital Products INC. | $110.34 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $106.91 | 2022-2023 | Ultomiris, Soliris |
| Baxter Healthcare | $88.10 | 2023-2024 | Renal - Pd, Renal - Acute |
| Akebia Therapeutics INC | $83.23 | 2024-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $72.04 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $25.26 | 2025 | Purified Cortrophin Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.51 | 2023 | Injectafer |
| Fresenius USA Marketing, INC. | $20.98 | 2022 | |
| Horizon Therapeutics Plc | $19.15 | 2022 | |
| Aurinia Pharma U.S., INC. | $17.68 | 2025 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $16.48 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorrie Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.